DCF Tool


DuPont de Nemours Inc – Plastics Material and Resin Manufacturing
dupont (www.dupont.com) is a science-based products and services company. founded in 1802, dupont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. operating in more than 90 countries, dupont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation. we look forward to having a dialogue with you here. please take the time to review our comments policy before commenting on our page. http://dptn.ws/policy
Analysis Results
Intrinsic Value $157.67
Latest Price $71.08
Relative Value 55% undervalued
Thoughts on this result? Let us know.
Cash Flow (Billions)
Analysis Parameters
New Ticker
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of -3.4%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 4.3%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of -3.4%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (billion) Present value (billion)
2023 2.78 2.66
2024 2.68 2.47
2025 2.59 2.28
2026 2.5 2.11
2027 2.42 1.96
Terminal Value

Assuming the company was sold after the projection period at an exit multiple of 30, the terminal value of the company would be 72.5 billion. This corresponds to a present value of 56.3 billion.

Intrinsic Value Per Share

The total present value of the projected cash flows is 11.5 billion. Adding in the terminal value gives a total present value of 67.8 billion.

There are presently 430.0 million outstanding shares, so the intrinsic value per share is 157.67.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 11,270,000,000
Current Cash 4,964,000,000
Current Liabilities 3,733,000,000
Current Debt 300,000,000
Non-Cash Working Capital (NCWC) 2,873,000,000
Change in NCWC 931,000,000
EBIT 2,097,000,000
Tax Provision 387,000,000
Depreciation and Amortization 1,180,000,000
Capital Expenditure -743,000,000
Unlevered Free Cash Flow 2,904,544,889
Current Assets 8,065,000,000
Current Cash 2,011,000,000
Current Liabilities 4,262,000,000
Current Debt 150,000,000
Non-Cash Working Capital (NCWC) 1,942,000,000
Change in NCWC -1,697,000,000
EBIT 2,746,000,000
Tax Provision 392,000,000
Depreciation and Amortization 1,458,000,000
Capital Expenditure -891,000,000
Unlevered Free Cash Flow 1,125,821,493
Current Assets 10,877,000,000
Current Cash 2,544,000,000
Current Liabilities 4,699,000,000
Current Debt 5,000,000
Non-Cash Working Capital (NCWC) 3,639,000,000
Change in NCWC -304,000,000
EBIT 1,852,000,000
Tax Provision -23,000,000
Depreciation and Amortization 3,094,000,000
Capital Expenditure -1,194,000,000
Unlevered Free Cash Flow 3,448,000,000
Current Assets 9,999,000,000
Current Cash 1,540,000,000
Current Liabilities 8,346,000,000
Current Debt 3,830,000,000
Non-Cash Working Capital (NCWC) 3,943,000,000
Change in NCWC -10,131,000,000
EBIT 2,872,000,000
Tax Provision 140,000,000
Depreciation and Amortization 3,195,000,000
Capital Expenditure -2,497,000,000
Unlevered Free Cash Flow -6,561,000,000
Current Assets 49,603,000,000
Current Cash 13,616,000,000
Current Liabilities 24,715,000,000
Current Debt 2,802,000,000
Non-Cash Working Capital (NCWC) 14,074,000,000
Change in NCWC 688,000,000
EBIT 9,973,000,000
Tax Provision 1,489,000,000
Depreciation and Amortization 5,918,000,000
Capital Expenditure -3,977,000,000
Unlevered Free Cash Flow 9,898,596,213
Current Assets 49,893,000,000
Current Cash 14,394,000,000
Current Liabilities 26,128,000,000
Current Debt 4,015,000,000
Non-Cash Working Capital (NCWC) 13,386,000,000
Change in NCWC 8,031,000,000
EBIT 5,690,000,000
Tax Provision -476,000,000
Depreciation and Amortization 3,969,000,000
Capital Expenditure -3,878,000,000
Unlevered Free Cash Flow 13,812,000,000
Current Assets 23,659,000,000
Current Cash 6,607,000,000
Current Liabilities 12,604,000,000
Current Debt 907,000,000
Non-Cash Working Capital (NCWC) 5,355,000,000
Change in NCWC -323,000,000
EBIT 5,527,000,000
Tax Provision 9,000,000
Depreciation and Amortization 2,862,000,000
Capital Expenditure -3,804,000,000
Unlevered Free Cash Flow 4,250,728,076
Current Assets 24,475,000,000
Current Cash 8,577,000,000
Current Liabilities 11,215,000,000
Current Debt 995,000,000
Non-Cash Working Capital (NCWC) 5,678,000,000
Change in NCWC -2,287,000,000
EBIT 6,628,000,000
Tax Provision 2,147,000,000
Depreciation and Amortization 2,521,000,000
Capital Expenditure -3,703,000,000
Unlevered Free Cash Flow 1,725,936,958
Current Assets 24,267,000,000
Current Cash 5,654,000,000
Current Liabilities 11,593,000,000
Current Debt 945,000,000
Non-Cash Working Capital (NCWC) 7,965,000,000
Change in NCWC -241,000,000
EBIT 6,349,000,000
Tax Provision 1,426,000,000
Depreciation and Amortization 2,747,000,000
Capital Expenditure -3,620,000,000
Unlevered Free Cash Flow 3,515,403,798
Current Assets 24,977,000,000
Current Cash 5,940,000,000
Current Liabilities 11,971,000,000
Current Debt 1,140,000,000
Non-Cash Working Capital (NCWC) 8,206,000,000
Change in NCWC -735,000,000
EBIT 5,288,000,000
Tax Provision 1,988,000,000
Depreciation and Amortization 2,681,000,000
Capital Expenditure -2,302,000,000
Unlevered Free Cash Flow 3,386,946,502
Current Assets 23,684,000,000
Current Cash 4,318,000,000
Current Liabilities 11,493,000,000
Current Debt 1,068,000,000
Non-Cash Working Capital (NCWC) 8,941,000,000
Change in NCWC 1,309,000,000
EBIT 4,483,000,000
Tax Provision 565,000,000
Depreciation and Amortization 2,698,000,000
Capital Expenditure -2,614,000,000
Unlevered Free Cash Flow 4,354,741,741

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.